Methods and device to neutralize soluble toxic agents in the brain

• US 9,580,494 B2
• Filed: 05/22/2015
• Issued: 02/28/2017
• Est. Priority Date: 05/14/2007
• Status: Active Grant

• Current Assignee: Medtronic Incorporated (Medtronic Plc)
• Original Assignee: Medtronic Incorporated (Medtronic Plc)
• Inventors: Shafer, Lisa Lynn, Thakker, Deepak Ramesh
• Primary Examiner(s): Weidner, Adam M
• Application Number:
  US14/719,795
• Publication Number:
  US 20160152695A1
• Time in Patent Office: 648 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/54 characterised by the route of administration
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 2317/54 F(ab')2

Abstract

Methods, agents and devices for treating a patient to reduce accumulation of certain proteins in the brain are described. Such proteins include amyloid beta (Aβ), and the methods, agents and devices are useful for reducing the accumulation of Aβ, which is a principal constituent of the plaques associated with such diseases as Alzheimer'"'"'s disease (AD). Antibodies to Aβ, when delivered systemically or directly into the central nervous system, improve cognitive deficits in a transgenic mouse model of AD. However, unlike peripheral antibodies to Aβ, which increased cerebral vascular plaques and hemorrhages, direct central administration did not result in such an increase cerebral vascular plaques and hemorrhages.

Claims

1. A method for clearing cerebral vascular amyloid plaques in a subject in need thereof, comprising:

chronically delivering to a cerebral ventricle of the subject an anti-Aβ

antibody in an amount effective to clear the cerebral vascular amyloid plaques,

wherein the anti-Aβ

antibody is chronically delivered to the subject'"'"'s cerebral ventricle from a reservoir of an implantable infusion device.

2. The method of claim 1, wherein the antibody binds Aβ

42.

3. The method of claim 1, wherein the antibody binds Aβ

40.

4. The method of claim 1, wherein the antibody binds an intracellular Aβ

3.

5. The method of claim 1, wherein the antibody comprises an immunoglobulin domain.

6. The method of claim 1, wherein the antibody is a F(ab′

)2 fragment.

7. A method for treating a subject having a cerebral vascular disease associated with increased or aberrant soluble amyloid beta (Aβ

), amyloid fibrils, or amyloid plaques, wherein the disease is selected from the group consisting of Lewy body dementia and Down'"'"'s syndrome, the method comprising;

chronically delivering to a cerebral ventricle of the subject an anti-Aβ

antibody in an amount effective to treat the disease and to clear cerebral vascular amyloid plaques in the subject,

wherein the anti-Aβ

antibody is chronically delivered to the subject'"'"'s cerebral ventricle from a reservoir of an implantable infusion device.

8. The method of claim 7, wherein chronically delivering the antibody comprises delivering a composition comprising the antibody for a month or longer.

9. The method of claim 8, wherein delivering the antibody for a month or longer comprises delivering the composition comprising the antibody continuously for a month or longer.

10. The method of claim 9, wherein delivering the antibody continuously comprises delivering pulsed boluses of the composition comprising the antibody.

11. A method for treating Alzheimer'"'"'s disease and clearing cerebral vascular amyloid plaques in a subject in need thereof, comprising:

chronically delivering to a cerebral ventricle of the subject an anti-Aβ

antibody in an amount effective to treat the Alzheimer'"'"'s disease and clear the cerebral vascular amyloid plaques,

wherein the anti-Aβ

antibody is chronically delivered to the subject'"'"'s cerebral ventricle from a reservoir of an implantable infusion device.

12. The method of claim 11, wherein the antibody binds Aβ

42.

13. The method of claim 11, wherein the antibody binds Aβ

40.

14. The method of claim 11, wherein the antibody binds an intracellular Aβ

.

15. The method of claim 11, wherein the antibody comprises an immunoglobulin domain.

16. The method of claim 11, wherein the antibody is a F(ab′

)2 fragment.

17. The method of claim 11, further comprising introducing a composition comprising the antibody to the reservoir.

18. The method of claim 11, wherein chronically delivering the antibody comprises delivering a composition comprising the antibody for a month or longer.

19. The method of claim 18, wherein delivering the antibody for a month or longer comprises delivering the composition comprising the antibody continuously for a month or longer.

20. The method of claim 19, wherein delivering the antibody continuously comprises delivering pulsed boluses of the composition comprising the antibody.